临床中的药物基因组学
Mary V Relling1, William E Evans1
1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Nature
|October 16, 2015
概括
约20个基因的药物基因组变异影响80种药物,指导临床药物选择. 努力从发现转向实施基于证据的准确医学策略.
科学领域:
- 药物基因组学
- 遗传学
- 临床药理学
背景情况:
- 几十年的研究发现了影响药物反应的遗传基因变异.
- 已知大约有20种基因会影响大约80种药物的有效性和安全性.
- 人体基因变异越来越多地用于指导向的抗癌药物选择.
研究的目的:
- 总结目前的药物基因组知识及其临床应用.
- 突出从遗传发现到临床实施的转变.
- 强调药物基因组学在精确医学的发展中的作用.
主要方法:
- 检查发现的基因变异及其相关药物.
- 分析当前的临床实践和实施策略.
- 综合证据支持药物基因组指导治疗.
主要成果:
- 对于影响80种药物的大约20种基因,有可操作的药物基因组信息.
- 身体基因变异对于选择向癌症疗法至关重要.
- 药物基因组学的临床应用日益受到重视.
结论:
- 药物基因组学是精准医学的基石.
- 基于证据的实施策略对于优化药物使用至关重要.
- 需要继续努力将药物基因学变异性纳入常规临床实践.
相关概念视频
Pharmacogenetics and Pharmacogenomics: Overview
147
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
147
Pharmacogenomics: Identification of New Drug Targets
84
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics of Drug Metabolism: Overview
117
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
117
Principles of Pharmacogenetics: Types of Genetic Variants
97
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
97
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
163
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
163


